PULMATRIX, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value
PULMATRIX, INC. (PULM) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value of $1.59 million for the 12-month period ending 2015-03-31, per its 10-K filed 2015-06-10.
Discontinued › Notes › Share-Based Payment Arrangement › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 · last filed 2015-06-10
- PULMATRIX, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2015-03-31 was $0.00.
- PULMATRIX, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2014-12-31 was $0.00.
- PULMATRIX, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2014-09-30 was $0.00.
- PULMATRIX, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2014-06-30 was $1.59M.
- PULMATRIX, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2015 was $1.59M.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 12 month |
|---|---|---|---|---|
| 2015-03-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2015-06-10 | $0.00 derived: sum of 2 quarters · filed 2015-06-10 | $0.00 derived: sum of 3 quarters · filed 2015-06-10 | $1.59M 10-K · filed 2015-06-10 |
| 2014-12-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2015-02-13 | $0.00 derived: sum of 2 quarters · filed 2015-02-13 | $1.59M 10-Q · filed 2015-02-13 | |
| 2014-09-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2014-11-13 | $1.59M 10-Q · filed 2014-11-13 | ||
| 2014-06-30 | $1.59M 10-Q · filed 2014-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |